Shilpa Medicare’s wholly owned subsidiary-- Shilpa Biocare has entered into a strategic equity partnership with Gate2Brain, S.L. (Gate2Brain), a biotechnology company pioneering peptide-shuttle therapeutics for central nervous system (CNS) diseases. Under the terms of the agreement, Shilpa becomes a strategic shareholder of Gate2Brain and its dedicated CMC, manufacturing, and regulatory partner for G2B-002--Gate2Brain's lead program in brain cancer.
G2B-002 has been granted Orphan Drug Designation (ODD) by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), underscoring its potential in rare and aggressive pediatric and adult brain tumors. The candidate is designed to target diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM)-- two of the most lethal childhood brain cancers, with very limited treatment options today. G2B-002 delivers SN-38, a potent anticancer agent, across the blood-brain barrier (BBB) via Gate2Brain's proprietary MiniAp4 peptide shuttle.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
